- NovaBay Pharmaceuticals ( NYSE: NBY ) on Tuesday said it received significant orders for DERMAdoctor Kakadu C anti-aging serum ahead of the holiday season.
- "These orders will favorably impact DERMAdoctor’s revenue contribution for the 2022 third and fourth quarters," said NovaBay CEO Justin Hall.
- The company noted that the serum helps to brighten and even skin tone and improves the appearance of skin elasticity, fine lines and wrinkles.
- NBY +4.79% to $0.11 premarket Oct. 18
For further details see:
NovaBay stock rises on orders for Kakadu anti-aging serum